RNF31 induces paclitaxel resistance by sustaining ALYREF cytoplasmic–nuclear shuttling in human triple-negative breast cancer

Shumei Huang; Dongni Shi; Shuqin Dai; Xingyu Jiang; Rui Wang; Muwen Yang; Boyu Chen; Xuwei Chen; Lingzhi Kong; Lixin He; Pinwei Deng; Xiangfu Chen; Chuyong Lin; Yue Li; Jun Li; Libing Song; Yawei Shi; Weidong Wei

doi:10.1002/ctm2.70203

Clinical and Translational Medicine ›› 2025, Vol. 15 ›› Issue (2) : e70203 DOI: 10.1002/ctm2.70203

RESEARCH ARTICLE

RNF31 induces paclitaxel resistance by sustaining ALYREF cytoplasmic–nuclear shuttling in human triple-negative breast cancer

Author information +

History +

PDF

Abstract

	•RNF31 facilitated ALYREF-mediated PTX resistance in TNBC.
	•RNF31 promoted ALYREF nuclear transport via IPO13 in response to PTX treatment, subsequently enhancing the export of mRNAs encoding PTX resistance-related factors, including TUBB3, STMN1, and TAU.
	•Blocking RNF31 trapped ALYREF in the cytoplasm and induced TNBC cell death upon PTX treatment.
	•Inhibiting RNF31 activity re-sensitized PTX-resistant TNBC to PTX treatment.

Keywords

ALYREF / cytoplasmic–nuclear shuttling / paclitaxel resistance / triple-negative breast cancer

Cite this article

Download citation ▾

Shumei Huang,Dongni Shi,Shuqin Dai,Xingyu Jiang,Rui Wang,Muwen Yang,Boyu Chen,Xuwei Chen,Lingzhi Kong,Lixin He,Pinwei Deng,Xiangfu Chen,Chuyong Lin,Yue Li,Jun Li,Libing Song,Yawei Shi,Weidong Wei. RNF31 induces paclitaxel resistance by sustaining ALYREF cytoplasmic–nuclear shuttling in human triple-negative breast cancer. Clinical and Translational Medicine, 2025, 15(2): e70203 DOI:10.1002/ctm2.70203

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

RIGHTS & PERMISSIONS

2025 The Author(s). Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.